The Center of Cardiovascular Diseases, the First Hospital of Jilin University, Changchun, 130021, China.
Pediatric Research Institute, the Department of Pediatrics of University of Louisville, Louisville, 40202, USA.
Acta Pharmacol Sin. 2018 Jul;39(7):1073-1084. doi: 10.1038/aps.2018.30. Epub 2018 Jun 7.
Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in the world. Although considerable progress has been made in the diagnosis, treatment and prognosis of CVD, there is still a critical need for novel diagnostic biomarkers and new therapeutic interventions to decrease the incidence of this disease. Recently, there is increasing evidence that circulating miRNAs (miRNAs), i.e. endogenous, stable, single-stranded, short, non-coding RNAs, can be used as diagnostic biomarkers for CVD. Furthermore, miRNAs represent potential novel therapeutic targets for several cardiovascular disorders. In this review we provides an overview of the effects of several CVD; including heart failure, acute myocardial infarction, arrhythmias and pulmonary hypertension; on levels of circulating miRNAs. In addition, the use of miRNA as therapeutic targets is also discussed, as well as challenges and recommendations in their use in the diagnosis of CVD.
心血管疾病（CVD）是世界上发病率和死亡率的主要原因。尽管在 CVD 的诊断、治疗和预后方面已经取得了相当大的进展，但仍迫切需要新的诊断生物标志物和新的治疗干预措施来降低这种疾病的发生率。最近，越来越多的证据表明，循环 miRNA（miRNA），即内源性、稳定、单链、短、非编码 RNA，可以作为 CVD 的诊断生物标志物。此外，miRNA 代表了几种心血管疾病的潜在新的治疗靶点。在这篇综述中，我们概述了几种 CVD（包括心力衰竭、急性心肌梗死、心律失常和肺动脉高压）对循环 miRNA 水平的影响。此外，还讨论了 miRNA 作为治疗靶点的应用，以及在 CVD 诊断中使用 miRNA 时面临的挑战和建议。
